Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis
Tuğba Karakavuk1,2, Ceren Gül1,2, Muhammet Karakavuk1,3
1Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye
Turkiye Parazitolojii Dergisi
|November 29, 2022
Summary
Toxoplasma gondii infects many animals and humans, causing disease in the immunocompromised. Recombinant protein vaccines offer a promising, broadly applicable approach to prevent toxoplasmosis.
Area of Science:
- Parasitology
- Immunology
- Biotechnology
Background:
- Toxoplasma gondii is a widespread parasite infecting humans and animals, posing risks particularly to immunocompromised individuals.
- Transmission occurs through contaminated food, water, animal products, and congenital routes, leading to significant economic losses in livestock.
- Current vaccines are limited, highlighting the need for innovative, broadly applicable vaccines against toxoplasmosis.
Conclusions:
- Recombinant protein vaccines represent a promising strategy for controlling toxoplasmosis due to their versatility and efficacy.
- Further research into novel antigens and expression systems can enhance vaccine development.
- Biotechnological advancements are crucial for creating safe, effective, and widely usable vaccines against T. gondii.
